## Timing of Surgery in Ewing Sarcoma: Neoadjuvant Response **Key Point:** Once a good neoadjuvant response is documented (typically ≥50% reduction in tumor volume on imaging after 6–8 weeks of chemotherapy), surgery should proceed promptly to achieve local control while maintaining systemic chemotherapy schedule. ### Rationale for Proceeding to Surgery 1. **Documented chemosensitivity** — 60% volume reduction indicates good response and predicts better prognosis. 2. **Surgical resectability confirmed** — Tumor shrinkage improves the chance of limb-salvage surgery with adequate margins. 3. **Timing optimization** — Prolonged delay between neoadjuvant therapy and surgery increases risk of tumor regrowth and resistance; surgery is typically performed 6–12 weeks after starting chemotherapy. 4. **Adjuvant therapy continuation** — Post-operative chemotherapy will continue to treat micrometastases. ### Modern Multimodal Therapy Timeline ```mermaid flowchart TD A[Ewing sarcoma diagnosed<br/>Staging complete]:::outcome --> B[Neoadjuvant chemotherapy<br/>VAC/IE x 6-8 weeks]:::action B --> C{Imaging response?}:::decision C -->|Good response<br/>≥50% reduction| D[Wide surgical excision<br/>Limb-salvage preferred]:::action C -->|Poor response| E[Consider amputation<br/>or radiation]:::action D --> F[Adjuvant chemotherapy<br/>Continue VAC/IE]:::action E --> F F --> G[Local radiation if<br/>inadequate margins]:::action G --> H[Long-term follow-up<br/>5-year survival goal]:::outcome ``` **Clinical Pearl:** Limb-salvage surgery is now standard in Ewing sarcoma when margins can be achieved without neurovascular compromise. Amputation is reserved for cases with poor response, vascular involvement, or pathological fracture with soft tissue spread. **High-Yield:** The presence of good neoadjuvant response (≥90% necrosis on histology) is the strongest predictor of improved overall survival in Ewing sarcoma. Proceeding to surgery after documented response is the standard of care. ### Why Continued Chemotherapy Before Surgery Is Suboptimal While total chemotherapy duration is important, prolonging the interval between neoadjuvant therapy and surgery risks: - Tumor regrowth and re-expansion - Development of chemotherapy resistance - Loss of surgical window for optimal resection Surgery should follow within 6–12 weeks of starting chemotherapy. ### Why Amputation Is Not Indicated Here Amputation is reserved for: - Tumors with poor neoadjuvant response - Vascular or nerve involvement precluding limb-salvage - Pathological fracture with extensive soft tissue disease This patient has good response and resectable disease, making limb-salvage appropriate. 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.